Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

Home
/
update
/
details

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

NextEdge Admin

31 Oct 2024

2 min 0 sec

non-small cell lung cancer,AstraZeneca,Daiichi Sankyo

The first patients have been dosed in three global phase 3 trials assessing datopotamab deruxtecan (Dato-DXd)-based therapies for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Datopotamab deruxtecan, a TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo, is co-developed with AstraZeneca.

The TROPION-Lung10 trial examines datopotamab deruxtecan combined with rilvegostomig—AstraZeneca’s PD-1/TIGIT bispecific antibody—or rilvegostomig alone, versus pembrolizumab in patients with high PD-L1 expression (≥50%) without actionable mutations. TROPION-Lung14 evaluates the combination of datopotamab deruxtecan and osimertinib, AstraZeneca's EGFR tyrosine kinase inhibitor, against osimertinib alone in untreated, EGFR-mutated nonsquamous NSCLC. TROPION-Lung15 assesses datopotamab deruxtecan, with or without osimertinib, compared to platinum-based chemotherapy in patients with advanced EGFR-mutated NSCLC that progressed after osimertinib.

“These trials are essential to understanding datopotamab deruxtecan’s potential in treating different lines and types of lung cancer,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development at Daiichi Sankyo. “Our expanding TROPION program underscores our commitment to lung cancer research.”

AstraZeneca’s Chief Medical Officer, Cristian Massacesi, MD, added, “Combining an ADC with targeted or bispecific immunotherapies may produce more durable tumor responses. These phase 3 trials reflect our pursuit of innovative combination therapies within our oncology pipeline and for TROP2-directed ADCs across NSCLC settings.”